By Hannah Albarazi ( January 8, 2020, 4:06 PM EST) -- The Federal Circuit on Tuesday summarily affirmed the Patent Trial and Appeal Board's inter partes review decisions invalidating a key patent for AbbVie Biotechnology Ltd.'s top-selling Humira, an immunosuppressant drug that brought in more than $13.6 billion in U.S. sales revenue in 2018....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.